Aalto Bio to receive war chest for M&A deals as firm is acquired
The medtech company provides raw materials, including proteins, antigens and antibodies, to the global diagnostics sector
Aalto Bio, which makes raw materials for diagnostic tests for infectious diseases, has been acquired in a multimillion-euro deal that will result in a combined entity with revenues of €100 million and around 450 staff.
Biosynth Carbosynth, a Swiss-headquartered company backed by KKR, a global investment firm, has bought Aalto for an undisclosed sum. It is to provide it with a war chest to make a large number of bolt-on acquisitions as it looks to ...